 Home > Active Ingredient News > Blood System > Nat Med: Bispecific CAR-T therapy targeting CD19 and CD22 can treat relapsed/refractory B-cell malignancies

Nat Med: Bispecific CAR-T therapy targeting CD19 and CD22 can treat relapsed/refractory B-cell malignancies

 Last Update: 2021-07-30
 Source: Internet
 Author: User

Tags

vortex 1 10

10 22 cleaning

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Previous studies have shown that the anti-tumor effects of chimeric antigen receptor-modified T cells ( CAR-T ) and natural killer (NK) cells targeting CD19 (CAR19) promote the treatment of relapsed/refractory B-cell malignancies Change

The anti-tumor effects of chimeric antigen receptor-modified T cells ( CAR-T ) and natural killer (NK) cells targeting CD19 (CAR19) have promoted the transformation of treatment strategies for relapsed/refractory B-cell malignancies

However, among patients treated with CAR-T (CAR19) targeting CD19, more than 50% of patients still have disease progression

In B acute lymphoblastic leukemia (B-ALL) cases, the 30-95% recurrence rate after CAR19 treatment is related to the loss of CD19 on the cell surface

^-^LOThis study aimed to phase I clinical trial in relapsed / refractory B-ALL, and patient LBCL (NCT03233854) was tested targeting CD19 and / or CD22 bispecific CAR-T therapy

Changes in the composition and phenotype of CAR products

In B-ALL patients (n=17), 100% of the patients responded to treatment, accompanied by 88% of minimal residual disease negative complete remission (CR); in LBCL patients (n=21), 62% The patient responded to treatment and had a CR of 29%

CD19/22-CAR-T is active in LBCL and B-ALL

All in all, the results of the study further show that the loss of antigen is the main cause of resistance to CAR-T cell therapy

Designing multi-specific CAR-T cells with cross-target equivalent potency may improve the efficacy of the therapy, and the production of cytokines is an important quality indicator of the efficacy of CAR-T therapy

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gadusol Powder Gadusol76663-30-4

CAS No.: 76663-30-4

Industrial Grade

$1-1.01/G FOB

Food Additive Iron fumarate for Nutritional Iron Supplements

CAS No.: 141-01-5

Pharmacy Grade

$24-26/G FOB

Aminobenzoic Acid CAS 56-91-7

CAS No.: 56-91-7

Pharmaceutical Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.